RTOG Foundation

RTOG Foundation opens new study testing [177Lu]Lu-DOTA-TATE for adults with meningioma

The MOMENTUM-1 study is a phase II trial testing the radioactive drug [177Lu]Lu-DOTA-TATE in adult patients with progressive intracranial grade 1-3 meningioma. The study aims to determine if treatment with [177Lu]Lu-DOTATate improves progression-free survival compared to standard medical therapy.

SourceRTOG Foundation·DateNov 4, 2025

RadComp Study health-related quality of life analysis shows benefit in both proton and photon radiation options in breast cancer patients

The RadComp study found that both proton and photon radiation treatment options yielded excellent health-related quality of life (HRQOL) outcomes for women with non-metastatic breast cancer. The trial, which compared HRQOL tools, showed no significant differences between the two treatments at 6 months following treatment.

SourceRTOG Foundation·DateSep 30, 2025